The post

The post

GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).

GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).

WEDNESDAY, Sept. 11, 2024 -- A proteomic signature indicating increased respiratory susceptibility identifies the risk for respiratory death, incident...

Hair loss will affect everyone at some point in their life. But, despite its prevalence, treating baldness is big business. In Europe, for example,...

“The size of the country's labour force is reduced by low life expectancy at around 64.3 years of age, which is itself a result of the low level of...

A new discovery by researchers at the University of Pittsburgh suggests that dietary changes could help treat pulmonary hypertension, a serious lung...

The US Presidential Election 2024 brings two distinct healthcare visions from Kamala Harris and Donald Trump, reflecting broader ideological...

A REDUCTION in air pollution can yield significant public health gains, but also help to tackle the escalating climate problem. “Non-communicable...